Archive Newsletter

  1. 03.24.25 -- Delivery Advances In Treating Bowel And Bladder Dysfunction 3/24/2025
    03/24/25 Drug Delivery Leader Newsletter
  2. 03.17.25 -- Managing Risk When Developing Combination Products 3/17/2025
    03/17/25 Drug Delivery Leader Newsletter
  3. 03.13.25 -- Frankly Fran: Subcutaneous Self-Administration: 3 Key Market Drivers, 3 Key Delivery Challenges 3/13/2025
    03/13/25 Drug Delivery Leader Newsletter
  4. 03.10.25 -- Accelerating Antibody Delivery With Surf Bio's Bryan Mazlish 3/10/2025
    03/10/25 Drug Delivery Leader Newsletter
  5. 03.04.25 -- Advancing Drug Design: Innovations In Bioavailability & Nanotechnology 3/4/2025

    03/04/25 Drug Delivery Leader Newsletter

  6. Best of February: Top 5 Insights In Drug Formulation & Delivery 3/3/2025
  7. 03.03.25 -- Combination Products: Early-Stage Formulation, Device Considerations 3/3/2025
    03/03/25 Drug Delivery Leader Newsletter
  8. 02.24.25 -- Integrating Development Processes For Combination Products 2/24/2025
    02/24/25 Drug Delivery Leader Newsletter
  9. 02.17.25 -- Broadening The Range Of Self-Administered Biologics 2/17/2025
    02/17/25 Drug Delivery Leader Newsletter
  10. 02.13.25 -- Frankly Fran: Use-Related Risk Analysis: Considering The FDA Guidance On URRA 2/13/2025
    02/13/25 Drug Delivery Leader Newsletter